Skip to content
preclinicalGrowth Hormone

Modified GRF 1-29

Also known as: Mod GRF 1-29, CJC-1295 without DAC, Tetrasubstituted GRF 1-29

Modified GRF 1-29 is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) that dramatically improve metabolic stability. Often confused with CJC-1295, Modified GRF 1-29 lacks the Drug Affinity Complex (DAC) that extends CJC-1295's half-life, resulting in shorter pulsatile GH release that more closely mimics natural physiology. It is widely used in research settings and by clinicians studying growth hormone optimization.

4 cited references·5 researched benefits

Quick Answer

Modified GRF 1-29 (Mod GRF) is a synthetic GHRH analog with four amino acid substitutions for enhanced metabolic stability. Unlike CJC-1295 with DAC, it produces short, pulsatile growth hormone release lasting 30 minutes, more closely mimicking natural GH secretion patterns. Commonly paired with GH secretagogues like ipamorelin or GHRP-2 for synergistic GH release, it is widely used in research and clinical settings studying growth hormone axis optimization.

Key Facts

Mechanism
Modified GRF 1-29 binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating Gs-coupled adenylyl cyclase and increasing intracellular cAMP. This stimulates transcription, synthesis, and pulsatile release of growth hormone. The four amino acid substitutions (D-Ala2 prevents DPP-4 cleavage, Gln8 resists asparagine-mediated amidation, Ala15 improves bioactivity, Leu27 prevents methionine oxidation) increase the half-life from native GHRH's ~7 minutes to approximately 30 minutes. Unlike CJC-1295 with DAC, it does not bind albumin, producing acute GH pulses rather than sustained elevation, which preserves the natural pulsatile GH secretion pattern and feedback mechanisms.
Research Status
preclinical
Half-Life
~30 minutes
Molecular Formula
C₁₅₂H₂₅₂N₄₄O₄₂
Primary Use
Growth Hormone
Table of Contents

Benefits

  • Pulsatile GH release — stimulates natural-pattern growth hormone pulses, preserving hypothalamic-pituitary feedback mechanismsmoderate
  • Synergistic with GHRPs — combining with ipamorelin or GHRP-2 produces 3–5× greater GH release than either peptide alonemoderate
  • Improved body composition — research subjects show decreased fat mass and increased lean body mass over 8–12 week protocolspreliminary
  • Enhanced recovery — may accelerate tissue repair and recovery through GH-mediated IGF-1 elevationpreliminary
  • Sleep quality — GH pulse enhancement during early sleep stages may improve deep sleep architectureanecdotal

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection100–300 mcg1–3× dailyTypically dosed at 100 mcg per injection, 1–3 times daily (morning, post-workout, before bed). Best administered on an empty stomach, as food (especially fats and carbohydrates) blunts GH release. Often combined with a GHRP (ipamorelin 100–200 mcg or GHRP-2 100–200 mcg) for synergistic effect.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Facial flushing — transient warmth and redness immediately following injection, lasting 5–15 minutescommon
  • Injection-site reactions — mild redness or irritation at subcutaneous injection sitecommon
  • Headache — occasional mild headache, particularly during initial userare
  • Water retention — mild fluid retention and joint stiffness with prolonged use, related to GH/IGF-1 elevationrare
  • Hypoglycemia — rare blood sugar drops when used in fasting state, as GH release can transiently affect glucose metabolismrare

Frequently Asked Questions

What is the difference between Modified GRF 1-29 and CJC-1295?
Both are GHRH analogs with the same 29-amino-acid core sequence and four substitutions. The key difference is the Drug Affinity Complex (DAC): CJC-1295 with DAC has a maleimidopropionic acid linker that binds serum albumin, extending its half-life to 6–8 days and producing sustained (non-pulsatile) GH elevation. Modified GRF 1-29 (CJC-1295 without DAC) has a ~30-minute half-life, producing short pulsatile GH release. Many researchers prefer Modified GRF 1-29 because pulsatile release better mimics natural physiology and may reduce receptor desensitization.
Why is Modified GRF 1-29 combined with ipamorelin?
This is one of the most popular peptide combinations because GHRH (Modified GRF 1-29) and GH secretagogues (ipamorelin) work through different receptors and pathways. GHRH stimulates GH synthesis and release via the GHRH receptor, while ipamorelin triggers GH release via the ghrelin/GHS receptor. Together, they produce synergistic GH output (3–5× greater than either alone) while maintaining the pulsatile release pattern. Ipamorelin also suppresses somatostatin, removing the physiological brake on GH release.
How does Modified GRF 1-29 differ from sermorelin?
Sermorelin is the natural GHRH(1-29) fragment without amino acid modifications, giving it a very short half-life (~7 minutes) and susceptibility to enzymatic degradation. Modified GRF 1-29 has four strategic substitutions that extend its half-life to ~30 minutes and increase biological potency. Sermorelin was FDA-approved for GH deficiency diagnosis (now discontinued), while Modified GRF 1-29 remains a research compound. For practical purposes, Modified GRF 1-29 produces more consistent GH stimulation per injection.
When should Modified GRF 1-29 be injected for optimal results?
GH release from Modified GRF 1-29 is blunted by elevated blood sugar, insulin, and free fatty acids. Therefore, injections are typically administered: (1) upon waking before eating (fasting state), (2) post-exercise when blood sugar is naturally lower, or (3) before bed to enhance the natural nocturnal GH pulse. Food should be avoided for at least 30 minutes before and after injection. High-fat or high-carbohydrate meals are particularly suppressive of GH release.
Is Modified GRF 1-29 FDA-approved?
No. Modified GRF 1-29 is not FDA-approved for any indication. It is available as a research chemical and is used in clinical research settings. The closely related compound sermorelin was previously FDA-approved for GH deficiency diagnosis but has been discontinued. CJC-1295 with DAC underwent phase 2 clinical trials but development was halted. Modified GRF 1-29 is widely available from research peptide suppliers but lacks regulatory approval for therapeutic use.

References

  1. 1
    Prolonged stimulation of growth hormone release by analogs of growth hormone-releasing factor(1986)PubMed ↗
  2. 2
    Growth hormone-releasing hormone analogs: chemistry, pharmacology, and clinical applications(2006)PubMed ↗
  3. 3
    Synergistic effects of GHRH and GHRP on growth hormone secretion in humans(1997)PubMed ↗
  4. 4
    Structure-activity relationships of growth hormone-releasing factor analogs(1990)PubMed ↗

Latest Research

Last updated: 2026-02-19